

Cosmetic Carrier

B
~~composition~~ is in a form of a member selected from the group consisting of ointment, cream, emulsion, lotion, facial pack and bath additive.

G3
18. An immunopotentiator for preventing ultraviolet light-induced skin immunosuppression comprising glutathione, the blend ratio of glutathione in the liniment, on a dry basis, being 0.01-10.0 wt%.

REMARKS

Appreciation is hereby expressed to Examiner Prats for the interview so courteously granted on June 27, 2000. Pursuant to that interview, Claims 1-4 have been rewritten to more definitely set forth the invention and obviate the rejections. Additionally, new claims 15-18 are presented which are likewise believed to patentably distinguish from the prior art of record. Support for the amendments herein can be found in the Specification on page 12, lines 17-25; page 14, lines 8-16. Claims 1-18 are in the application, claims 5-14 having been withdrawn as being directed to non-elected inventions.

Reconsideration is requested of the rejection of claims 1-4 under 35 U.S.C. § 112, second paragraph, as being indefinite. The claims have been amended to obviate the rejection which is now believed to be moot. Withdrawal of the rejection is therefore respectfully requested.

Reconsideration is respectfully requested of the rejection of

claims 1-4 under 35 U.S.C. § 102(e) as being anticipated by Hersh, et al.

Hersh, et al. are concerned with a protective composition for x-ray induced skin damage which includes glutathione and seleno amino acid in a topical carrier. There is no disclosure whatever in the Hersh, et al. reference of either a method or composition for preventing or controlling immunosuppression due to contact of the skin by ultraviolet light. On the contrary, that teaching or suggestion appears only in the present application and constitutes an important element or aspect of the present invention.

Failing a disclosure of these important elements of the present invention as now set forth in the amended claims, the Examiner would be justified in no longer maintaining the rejection. Withdrawal of the rejection is accordingly respectfully requested.


Reconsideration is respectfully requested of the rejection of Claims 1-4 under 35 U.S.C. § 102(b) as being anticipated by Matsuura, et al., or Hara, et al., or Demopolous, et al. or Oyama, et al. All of these references relied upon by the Examiner disclose the use of glutathione or its derivatives either alone or in combination with other compounds for topical application. However, there is no disclosure whatever in any of these references of a method for controlling or preventing immunosuppression due to contact of the skin by ultraviolet light by applying to the skin an endermic liniment comprising glutathione. On the contrary, that teaching or suggestion comes only from the present application and

constitutes an important element or aspect of the present invention. It is therefore respectfully submitted that the claims as amended now clearly distinguish from each of these prior art references. Consequently, the Examiner would be justified in no longer maintaining the rejection. Withdrawal of the rejection is accordingly requested.

In view of the foregoing, it is respectfully submitted that the application is now in condition for allowance and early action and allowance thereof is accordingly respectfully requested. In the event that there is any reason why the application cannot be allowed at the present time, it is respectfully requested that the Examiner contact the undersigned listed below.

Respectfully submitted

TOWNSEND & BANTA


Donald E. Townsend
Reg. No. 22,069

TOWNSEND & BANTA
1225 Eye Street, N.W.
Suite 500
Washington, D.C. 20005
(202) 682-4727

Date: January 27, 2000